Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Deggingen – page 9

1 295 clinical trials in Deggingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Deggingen at a glance
1 295
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 295 trials in Deggingen

Open in trial search

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Study of ZL-1310, BI 764532 and atezolizumab in patients with advanced small cell lung cancer and neuroendocrine tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Deggingen

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on heart failure prevention and managing atrial fibrillation, exploring new therapeutic approaches for cardiac conditions.

  • Heart Failure Prevention Studies
  • Cardioembolic Event Prevention
  • Blood Pressure Management

Research includes evaluation of novel drug combinations and preventive therapies for cardiovascular outcomes.

02 Metabolic Disorders

Comprehensive research on hypertriglyceridemia and Type 2 Diabetes Mellitus, testing new treatments for metabolic conditions.

  • Triglyceride Level Management
  • Diabetes Cardiovascular Outcomes
  • Metabolic Disease Therapies

Studies aim to improve treatment options and long-term patient outcomes in metabolic disorders.

03 Respiratory Medicine

Advanced research targeting Chronic Obstructive Pulmonary Disease, investigating new therapeutic approaches for respiratory conditions.

  • COPD Exacerbation Management
  • Respiratory Disease Treatment
  • Long-term Disease Control

Focus on reducing acute exacerbations and improving quality of life for COPD patients.

04 Other Therapeutic Areas

Studies addressing gout with hyperuricemia and various forms of hypertension, developing targeted treatments.

  • Uric Acid Management
  • Resistant Hypertension Studies
  • Long-term Safety Evaluations

Research aimed at developing effective treatments for complex medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.